Novel targeted therapy for neuroblastoma: silencing the MXD3 gene using siRNA-Reference-Cited by-同舟云学术

Novel targeted therapy for neuroblastoma: silencing the MXD3 gene using siRNA

Published:2017-05-31 Issue:3 Volume:82 Page:527-535
ISSN:0031-3998
Container-title:Pediatric Research
language:en
Short-container-title:Pediatr Res

Author:

Duong Connie,Yoshida Sakiko,Chen Cathy,Barisone Gustavo,Diaz Elva,Li Yueju,Beckett Laurel,Chung Jong,Antony Reuben,Nolta Jan,Nitin Nitin,Satake Noriko

Publisher

Springer Science and Business Media LLC

Subject

Pediatrics, Perinatology, and Child Health

Link

http://www.nature.com/articles/pr201774.pdf

Reference39 articles.

1. Schleiermacher G, Janoueix-Lerosey I, Delattre O . Recent insights into the biology of neuroblastoma. Int J Cancer 2014;135:2249–2261.

2. Neuroblastoma Treatment (PDQ(R)). Health Professional Version. PDQ Cancer Information Summaries: Bethesda, MD, 2002.

3. Cohen LE, Gordon JH, Popovsky EY et al, Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: high incidence of endocrine and growth problems. Bone Marrow Transplant 2014;49:502–508.

4. Young SW, Stenzel M, Jia-Lin Y . Nanoparticle-siRNA: a potential cancer therapy? Crit Rev Oncol Hematol 2016;98:159–169.

5. Koldehoff M, Steckel NK, Beelen DW, Elmaagacli AH . Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. Clin Exp Med 2007;7:47–55.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting pediatric solid tumors in the new era of RNA therapeutics;Critical Reviews in Oncology/Hematology;2024-08

2. Homoharringtonine as a PHGDH inhibitor: Unraveling metabolic dependencies and developing a potent therapeutic strategy for high-risk neuroblastoma;Biomedicine & Pharmacotherapy;2023-10

3. Neuroblastoma: Emerging trends in pathogenesis, diagnosis, and therapeutic targets;Journal of Controlled Release;2023-05

4. Nanomedicines and cell-based therapies for embryonal tumors of the nervous system;Journal of Controlled Release;2022-08

5. Overcoming doxorubicin resistance in cancer: siRNA-loaded nanoarchitectures for cancer gene therapy;Life Sciences;2022-06